UK regulators no longer exempt from paying successful parties' costs
26-05-2022
Shkreli says he isn’t responsible for Daraprim ‘monopoly’
30-07-2020
States join antitrust suit against ‘pharma bro’ Shkreli
16-04-2020
Mark Van Scyoc / Shutterstock.com
The US Federal Trade Commission (FTC) and New York’s attorney general have sued incarcerated ‘pharma bro’ Martin Shkreli for allegedly monopolising the market for life-saving drug Daraprim (pyrimethamine).
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Martin Shkreli, competition, antitrust, drug monopoly, Daraprim, Vyera Pharmaceuticals, Turing Pharmaceuticals, Letitia James, FTC
